A citation-based method for searching scientific literature

J A Ledermann, A C Embleton-Thirsk, T J Perren, G C Jayson, G J S Rustin, S B Kaye, H Hirte, A Oza, M Vaughan, M Friedlander, A González-Martín, E Deane, B Popoola, L Farrelly, A M Swart, R S Kaplan, M K B Parmar. ESMO Open 2021
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.
Bradley J Monk, Thomas J Herzog, Stanley B Kaye, Carolyn N Krasner, Jan B Vermorken, Franco M Muggia, Eric Pujade-Lauraine, Alla S Lisyanskaya, Anatoly N Makhson, Janusz Rolski,[...]. J Clin Oncol 2010
267
100

Ovarian cancer statistics, 2018.
Lindsey A Torre, Britton Trabert, Carol E DeSantis, Kimberly D Miller, Goli Samimi, Carolyn D Runowicz, Mia M Gaudet, Ahmedin Jemal, Rebecca L Siegel. CA Cancer J Clin 2018
957
100

Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer.
Joyce F Liu, Isabelle Ray-Coquard, Frederic Selle, Andrés M Poveda, David Cibula, Hal Hirte, Felix Hilpert, Francesco Raspagliesi, Laurence Gladieff, Philipp Harter,[...]. J Clin Oncol 2016
41
100

A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.
Amit M Oza, Ursula A Matulonis, Angeles Alvarez Secord, John Nemunaitis, Lynda D Roman, Sarah P Blagden, Susana Banerjee, William P McGuire, Sharad Ghamande, Michael J Birrer,[...]. Clin Cancer Res 2020
20
100

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
Jacobus Pfisterer, Marie Plante, Ignace Vergote, Andreas du Bois, Hal Hirte, Angel J Lacave, Uwe Wagner, Anne Stähle, Gavin Stuart, Rainer Kimmig,[...]. J Clin Oncol 2006
488
100

Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
Sharmila Makhija, Lukas C Amler, Dana Glenn, Frederick R Ueland, Michael A Gold, Don S Dizon, Virginia Paton, Chin-Yu Lin, Thomas Januario, Kimmie Ng,[...]. J Clin Oncol 2010
124
100

Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.
Robert L Coleman, James Moon, Anil K Sood, Wei Hu, James E Delmore, Albert J Bonebrake, Garnet L Anderson, Setsuko K Chambers, Maurie Markman. Eur J Cancer 2014
19
100

Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Radoslav Chekerov, Felix Hilpert, Sven Mahner, Ahmed El-Balat, Philipp Harter, Nikolaus De Gregorio, Claudius Fridrich, Susanne Markmann, Jochem Potenberg, Ralf Lorenz,[...]. Lancet Oncol 2018
35
100

A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission.
Stanley B Kaye, Louis Fehrenbacher, Robert Holloway, Amnon Amit, Beth Karlan, Brian Slomovitz, Paul Sabbatini, Ling Fu, Robert L Yauch, Ilsung Chang,[...]. Clin Cancer Res 2012
89
100

Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.
Amit Oza, Stanley Kaye, Jan Van Tornout, Cristiana Sessa, Martin Gore, R Wendel Naumann, Hal Hirte, Nicoletta Colombo, Jihong Chen, Seema Gorla,[...]. Gynecol Oncol 2018
13
100

Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical Benefit?
J C Del Paggio, B Azariah, R Sullivan, W M Hopman, F V James, S Roshni, I F Tannock, C M Booth. Ann Oncol 2017
45
100

Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
Gerald Falchook, Robert L Coleman, Andrzej Roszak, Kian Behbakht, Ursula Matulonis, Isabelle Ray-Coquard, Piotr Sawrycki, Linda R Duska, William Tew, Sharad Ghamande,[...]. JAMA Oncol 2019
39
100

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.
Bradley J Monk, Andrés Poveda, Ignace Vergote, Francesco Raspagliesi, Keiichi Fujiwara, Duk-Soo Bae, Ana Oaknin, Isabelle Ray-Coquard, Diane M Provencher, Beth Y Karlan,[...]. Lancet Oncol 2014
187
100

Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
Debra L Richardson, Michael W Sill, Robert L Coleman, Anil K Sood, Michael L Pearl, Siobhan M Kehoe, Michael E Carney, Parviz Hanjani, Linda Van Le, Xun C Zhou,[...]. JAMA Oncol 2018
31
100

ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†.
N Colombo, C Sessa, A du Bois, J Ledermann, W G McCluggage, I McNeish, P Morice, S Pignata, I Ray-Coquard, I Vergote,[...]. Ann Oncol 2019
207
100

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Carol Aghajanian, Stephanie V Blank, Barbara A Goff, Patricia L Judson, Michael G Teneriello, Amreen Husain, Mika A Sovak, Jing Yi, Lawrence R Nycum. J Clin Oncol 2012
781
100

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Amit M Oza, David Cibula, Ana Oaknin Benzaquen, Christopher Poole, Ron H J Mathijssen, Gabe S Sonke, Nicoletta Colombo, Jiří Špaček, Peter Vuylsteke, Holger Hirte,[...]. Lancet Oncol 2015
339
100


Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
Michael Friedlander, Ursula Matulonis, Charlie Gourley, Andreas du Bois, Ignace Vergote, Gordon Rustin, Clare Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. Br J Cancer 2018
68
100


Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Robert L Coleman, Mark F Brady, Thomas J Herzog, Paul Sabbatini, Deborah K Armstrong, Joan L Walker, Byoung-Gie Kim, Keiichi Fujiwara, Krishnansu S Tewari, David M O'Malley,[...]. Lancet Oncol 2017
243
100

A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse.
Ignace Vergote, Deborah Armstrong, Giovanni Scambia, Michael Teneriello, Jalid Sehouli, Charles Schweizer, Susan C Weil, Aristotelis Bamias, Keiichi Fujiwara, Kazunori Ochiai,[...]. J Clin Oncol 2016
61
100

Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.
Gabriella Ferrandina, Manuela Ludovisi, Domenica Lorusso, Sandro Pignata, Enrico Breda, Antonella Savarese, Pietro Del Medico, Laura Scaltriti, Dionyssios Katsaros, Domenico Priolo,[...]. J Clin Oncol 2008
190
100

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.
Jonathan A Ledermann, Andrew C Embleton, Fharat Raja, Timothy J Perren, Gordon C Jayson, Gordon J S Rustin, Stan B Kaye, Hal Hirte, Elizabeth Eisenhauer, Michelle Vaughan,[...]. Lancet 2016
129
100

Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma.
Hisamitsu Takaya, Hidekatsu Nakai, Shiro Takamatsu, Masaki Mandai, Noriomi Matsumura. Sci Rep 2020
33
100

Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.
Jalid Sehouli, Dirk Stengel, Guelten Oskay-Oezcelik, Alain G Zeimet, Harald Sommer, Peter Klare, Martina Stauch, Axel Paulenz, Oumar Camara, Elke Keil,[...]. J Clin Oncol 2008
101
100

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Eric Pujade-Lauraine, Felix Hilpert, Béatrice Weber, Alexander Reuss, Andres Poveda, Gunnar Kristensen, Roberto Sorio, Ignace Vergote, Petronella Witteveen, Aristotelis Bamias,[...]. J Clin Oncol 2014
766
100


Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial.
M Brundage, M Gropp, F Mefti, K Mann, B Lund, V Gebski, G Wolfram, N Reed, S Pignata, A Ferrero,[...]. Ann Oncol 2012
25
100


Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.
David G Mutch, Mauro Orlando, Tiana Goss, Michael G Teneriello, Alan N Gordon, Scott D McMeekin, Yanping Wang, Dennis R Scribner, Martin Marciniack, R Wendel Naumann,[...]. J Clin Oncol 2007
266
100

A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer.
S B Kaye, C J Poole, A Dańska-Bidzińska, L Gianni, G Del Conte, V Gorbunova, E Novikova, A Strauss, M Moczko, V A McNally,[...]. Ann Oncol 2013
62
100

Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All?
Andrew Berchuck, Angeles Alvarez Secord, Haley A Moss, Laura J Havrilesky. J Clin Oncol 2017
9
100

Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.
Stephanie Lheureux, Mihaela C Cristea, Jeffrey P Bruce, Swati Garg, Michael Cabanero, Gina Mantia-Smaldone, Alexander B Olawaiye, Susan L Ellard, Johanne I Weberpals, Andrea E Wahner Hendrickson,[...]. Lancet 2021
16
100

Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
Eric Pujade-Lauraine, Uwe Wagner, Elisabeth Aavall-Lundqvist, Val Gebski, Mark Heywood, Paul A Vasey, Birgit Volgger, Ignace Vergote, Sandro Pignata, Annamaria Ferrero,[...]. J Clin Oncol 2010
342
100


Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
David E Cohn, Michael W Sill, Joan L Walker, David O'Malley, Christa I Nagel, Teresa L Rutledge, William Bradley, Debra L Richardson, Katherine M Moxley, Carol Aghajanian. Gynecol Oncol 2017
25
100

ESMO-Magnitude of Clinical Benefit Scale version 1.1.
N I Cherny, U Dafni, J Bogaerts, N J Latino, G Pentheroudakis, J-Y Douillard, J Tabernero, C Zielinski, M J Piccart, E G E de Vries. Ann Oncol 2017
243
100

Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
Nicoletta Colombo, Elzbieta Kutarska, Meletios Dimopoulos, Duk-Soo Bae, Izabella Rzepka-Gorska, Mariusz Bidzinski, Giovanni Scambia, Svend Aage Engelholm, Florence Joly, Dirk Weber,[...]. J Clin Oncol 2012
84
100

A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
Ursula A Matulonis, Michael W Sill, Vicky Makker, David G Mutch, Jay W Carlson, Christopher J Darus, Robert S Mannel, David P Bender, Erin K Crane, Carol Aghajanian. Gynecol Oncol 2019
9
100

Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.
Stan B Kaye, Jan Lubinski, Ursula Matulonis, Joo Ern Ang, Charlie Gourley, Beth Y Karlan, Amit Amnon, Katherine M Bell-McGuinn, Lee-May Chen, Michael Friedlander,[...]. J Clin Oncol 2012
328
100

Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Sandro Pignata, Domenica Lorusso, Florence Joly, Ciro Gallo, Nicoletta Colombo, Cristiana Sessa, Aristotelis Bamias, Vanda Salutari, Frédèric Selle, Simona Frezzini,[...]. Lancet Oncol 2021
11
100

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.
W ten Bokkel Huinink, M Gore, J Carmichael, A Gordon, J Malfetano, I Hudson, C Broom, C Scarabelli, N Davidson, M Spanczynski,[...]. J Clin Oncol 1997
529
100


Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients.
U Wagner, C Marth, R Largillier, J Kaern, C Brown, M Heywood, T Bonaventura, I Vergote, M C Piccirillo, R Fossati,[...]. Br J Cancer 2012
98
100

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Mansoor R Mirza, Bradley J Monk, Jørn Herrstedt, Amit M Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A Ledermann, Domenica Lorusso, Ignace Vergote,[...]. N Engl J Med 2016
100



Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.
A N Gordon, J T Fleagle, D Guthrie, D E Parkin, M E Gore, A J Lacave. J Clin Oncol 2001
873
100

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Jacobus Pfisterer, Catherine M Shannon, Klaus Baumann, Joern Rau, Philipp Harter, Florence Joly, Jalid Sehouli, Ulrich Canzler, Barbara Schmalfeldt, Andrew P Dean,[...]. Lancet Oncol 2020
27
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.